[HTML][HTML] Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH
Parathyroid hormone (PTH) is the only Food and Drug Administration-approved anabolic
agent to treat osteoporosis; however, the cellular targets of PTH action in bone remain
controversial. PTH modulates bone turnover by binding to the PTH/PTH-related peptide
(PTHrP) type 1 receptor (PPR), a G-protein-coupled receptor highly expressed in bone and
kidneys. Osteocytes, the most abundant cells in adult bone, also express PPR. However, the
physiological relevance of PPR signaling in osteocytes remains to be elucidated. Toward …
agent to treat osteoporosis; however, the cellular targets of PTH action in bone remain
controversial. PTH modulates bone turnover by binding to the PTH/PTH-related peptide
(PTHrP) type 1 receptor (PPR), a G-protein-coupled receptor highly expressed in bone and
kidneys. Osteocytes, the most abundant cells in adult bone, also express PPR. However, the
physiological relevance of PPR signaling in osteocytes remains to be elucidated. Toward …